AI assistant
Novartis AG — Director's Dealing 2018
May 9, 2018
940_dirs_2018-05-09_f2aba7f1-4dc8-47f3-873c-582d39f93c94.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2018-05-07
Reporting Person: Novartis Bioventures Ltd (N/A)
Reporting Person: NOVARTIS AG (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-07 | Common Stock | S | 15548 | $10.11 | Disposed | 2295376 | Direct |
| 2018-05-08 | Common Stock | S | 26557 | $10.03 | Disposed | 2268819 | Direct |
Footnotes
F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.12. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.